© 2022 MJH Life Sciences and Contagion Live. All rights reserved.
© 2022 MJH Life Sciences™ and Contagion Live. All rights reserved.
Dr. Feuerstadt, a gastroenterologist, discusses foundational trials and ongoing studies in the use of fecal microbial transplantation (FMT) for treatment of recurrent C. difficile infections.
July 26th 2022
Dr Paul Feuerstadt provides an overview of Clostridioides difficile infection and why it is challenging to manage recurrent C diff infections (rCDI).
A gastroenterologist summarizes foundational trials that led to the use of fecal microbial transplant for treatment of rCDI.
Dr Feuerstadt discusses data with 4 emerging microbiota-based live biotherapeutics for treatment of rCDI: RBX2660, SER-109, CP101, and VE303.
FDA Approves Baloxavir Marboxil Flu Drug for Children
New CDC Guidelines Reduce Quarantine After COVID-19 Exposure
Omicron BA.4 and BA.5 Can’t Be Neutralized by Prior Infection
Next Generation Antimalarial MAB Targets Susceptibility of P falciparum